Ahmed Kotb/X
Jul 26, 2026, 13:32
Ahmed Kotb: A Practical Guide to Von Willebrand Disease
Ahmed Kotb, Hematologist and Bone Marrow Transplant Physician at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on X:
”Von Willebrand Disease (VWD)
Type 1: Partial decrease in von Willebrand factor (VWF) – usually responds to desmopressin (DDAVP).
Type 2: Qualitative defect in VWF.
- Type 2A: Decreased high-molecular-weight (HMW) multimers.
- Type 2B: Increased binding to platelet glycoprotein Ib (GPIb), resulting in thrombocytopenia; avoid DDAVP.
- Type 2M: Decreased platelet adhesion.
- Type 2N: Decreased binding to factor VIII (FVIII).
Type 3: Complete absence of VWF, causing severe disease; treat with VWF/FVIII concentrate.
Laboratory findings: Decreased VWF antigen, decreased VWF activity, and factor VIII may be decreased.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma